Vialwirebiotech, curated
September 30, 2026, 8:36 AM
September 12, 2026
- 3:09 AM · STAT News3:09 AMSTAT+: Breast cancer pill from AstraZeneca misses mark in pivotal trial — STAT News
September 11, 2026
- 7:30 PM · STAT News
- 6:17 PM · STAT News6:17 PMSTAT+: Pharma wins a battle over the cost of wastewater treatment in Europe — STAT News
- 12:00 PM · BioWorld12:00 PMSimtriyo, Lytenava headline FDA's July NME approvals — BioWorld
- 9:10 AM · Pharmaceutical Technology9:10 AMHIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir — Pharmaceutical Technology
- 4:35 AM · Pharmaceutical Technology4:35 AMABEC to expand global manufacturing network with new Wilson facility — Pharmaceutical Technology
- 4:30 AM · Drug Discovery World4:30 AMNew Phase IIa data for RESP-X revealed at ERS Congress 2026 — Drug Discovery World
- 4:30 AM · STAT News
- 2:01 AM · PharmaVoice2:01 AMMerck builds around Keytruda; prediction markets raise new risks — PharmaVoice
September 10, 2026
- 12:13 PM · BioPharma Dive12:13 PMFDA places partial hold on Biohaven’s epilepsy drug — BioPharma Dive
- 12:00 PM · BioWorld12:00 PMOpus BEST1 and done? Gene therapy scores in rare eye diseases — BioWorld
- 12:00 PM · BioWorld12:00 PMArchimed closes MED IV fund at €1.5 billion — BioWorld
- 12:00 PM · BioWorld12:00 PMAxogen to acquire Biocircuit for $200M — BioWorld
- 12:00 PM · BioWorld12:00 PMFDA setback delays Echo IQ's AI heart failure diagnostic ambitions — BioWorld
- 12:00 PM · BioWorld12:00 PMBayer’s Hyrnuo cleared as first-line HER2 lung cancer treatment — BioWorld
- 11:24 AM · BioPharma Dive11:24 AMAndy Plump, architect of Takeda’s R&D overhaul, to retire next year — BioPharma Dive
- 10:23 AM · Pharmaceutical Technology10:23 AMEncoded secures $275m for Dravet syndrome gene therapy — Pharmaceutical Technology
- 9:34 AM · Pharmaceutical Executive9:34 AM<![CDATA[Artisan Partners’ Director Calls for Novartis Board Shake-Up ]]> — Pharmaceutical Executive
- 9:00 AM · BioWorld9:00 AMNovartis’ PET tracer targets brain NLRP3 inflammasome — BioWorld
- 9:00 AM · BioWorld9:00 AMFull-Life’s [225Ac]Ac-FL-261 cleared for clinic in US, Australia — BioWorld
- 9:00 AM · BioWorld9:00 AM1cbio and Lee’s sign license deal for PARP1 inhibitor OC-3 — BioWorld
- 9:00 AM · BioWorld9:00 AMMighty Therapeutics begins IND-enabling studies of MYTX-255 — BioWorld
- 9:00 AM · BioWorld9:00 AMSchrödinger introduces Tectora Therapeutics — BioWorld
- 9:00 AM · BioWorld9:00 AMTwostep Therapeutics gains IND clearance for TS-104 — BioWorld
- 9:00 AM · BioWorld9:00 AMCDR-Life discloses T-cell engager for axial spondyloarthritis — BioWorld
- 9:00 AM · BioWorld9:00 AMAdagene earns milestone under Exelixis ADC collaboration — BioWorld